A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Trial Profile

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 214
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 10 Sep 2017 Results published in a Bristol-Myers Squibb media release.
    • 07 Sep 2017 Status changed from active, no longer recruiting to discontinued, according to a Bristol-Myers Squibb media release.
    • 07 Sep 2017 According to a Bristol-Myers Squibb media release, based on a planned interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. Results from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top